Growth Metrics

VYNE Therapeutics (VYNE) Cost of Revenue (2020 - 2021)

VYNE Therapeutics' Cost of Revenue history spans 2 years, with the latest figure at $903000.0 for Q4 2021.

  • For Q4 2021, Cost of Revenue rose 69.1% year-over-year to $903000.0; the TTM value through Dec 2021 reached $3.3 million, up 140.52%, while the annual FY2021 figure was $3.3 million, 140.52% up from the prior year.
  • Cost of Revenue reached $903000.0 in Q4 2021 per VYNE's latest filing, down from $1.0 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $1.0 million in Q3 2021 to a low of $216000.0 in Q2 2020.